Log in Free sign up

Aptinyx (APTX) News and press releases

News

From Benzinga Pro

This Healthcare Stock Jumps Around 188%, Here's 83 Biggest Movers From Yesterday

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) shares jumped 187.7% to close at $1.07 on Monday amid the Supreme Court overturning Roe V Wade.

Stocks That Hit 52-Week Lows On Friday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

During Friday's trading, 69 companies set new 52-week lows.

Stocks That Hit 52-Week Lows On Wednesday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Wednesday, 215 companies set new 52-week lows.

Expert Ratings for Aptinyx

Analyst Ratings

Within the last quarter, Aptinyx (NASDAQ:APTX) has observed the following analyst ratings:

Piper Sandler Maintains Overweight on Aptinyx, Lowers Price Target to $6

News, Price Target, Analyst Ratings

Piper Sandler analyst Christopher Raymond maintains Aptinyx (NASDAQ:APTX) with a Overweight and lowers the price target from $10 to $6.

Recap: Aptinyx Q1 Earnings

Aptinyx (NASDAQ:APTX) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Aptinyx beat estimated earnings by 3.33%, reporting an EPS of $-0.29 versus an estimate of $-0.3.

Aptinyx Q1 EPS $(0.29) Beats $(0.30) Estimate

Aptinyx (NASDAQ:APTX) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.30) by 3.33 percent. This is a 31.82 percent decrease over losses of $(0.22) per share from the same

Earnings Scheduled For May 12, 2022

Earnings, News, Pre-Market Outlook, Markets

Companies Reporting Before The Bell • Chicago Atlantic Real (NASDAQ:REFI) is projected to report earnings for its first quarter.

90 Biggest Movers From Yesterday

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Aptinyx To Present Preclinical Data On NYX-783 In Models Of PTSD At 2022 Society Of Biological Psychiatry Annual Meeting

Biotech, News, Events, General

Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today presented data from preclinical studies of NYX-783

Stocks That Hit 52-Week Lows On Thursday

News, Options, Intraday Update, Markets

During Thursday, 849 stocks hit new 52-week lows.

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Pre-Market Outlook, Markets, Movers

Expert Ratings for Aptinyx

Analyst Ratings

Within the last quarter, Aptinyx (NASDAQ:APTX) has observed the following analyst ratings:

SVB Leerink Maintains Outperform on Aptinyx, Lowers Price Target to $4

News, Price Target, Analyst Ratings

SVB Leerink analyst Marc Goodman maintains Aptinyx (NASDAQ:APTX) with a Outperform and lowers the price target from $10 to $4.

26 Stocks Moving in Thursday's Pre-Market Session

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers Redbox Entertainment Inc. (NASDAQ: RDBX) rose 31.9% to $3.35 in pre-market trading after jumping around 25% on Wednesday.

Aptinyx Announced Publication in Molecular Psychiatry Demonstrating Reduction of Spontaneous Recovery of Fear with NYX-783

News, Penny Stocks

Aptinyx Temporarily Pauses Initiation Of Phase 2b Study Of 150 mg Dose Of NYX-783 In PTSD Patients

Biotech, News, FDA, General

Aptinyx Inc. (NASDAQ:APTX) (the “Company”) has temporarily paused the initiation of its Phase 2b study of the 150 mg dose of NYX-783 in patients with post-traumatic stress disorder (“PTSD”). The

HC Wainwright & Co. Maintains Buy on Aptinyx, Lowers Price Target to $2

News, Price Target, Analyst Ratings

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Aptinyx (NASDAQ:APTX) with a Buy and lowers the price target from $8 to $2.

Truist Securities Maintains Buy on Aptinyx, Lowers Price Target to $5

News, Price Target, Analyst Ratings

Truist Securities analyst Joon Lee maintains Aptinyx (NASDAQ:APTX) with a Buy and lowers the price target from $12 to $5.

Cantor Fitzgerald Maintains Overweight on Aptinyx, Lowers Price Target to $5

News, Price Target, Analyst Ratings

Cantor Fitzgerald analyst Charles Duncan maintains Aptinyx (NASDAQ:APTX) with a Overweight and lowers the price target from $11 to $5.

Press releases

From Benzinga Pro

Aptinyx to Participate in H.C. Wainwright 1st Annual Mental Health Conference

Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that company management will present at the H.C.

Aptinyx to Participate in H.C. Wainwright Global Investment Conference

Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that company management will present at the H.C.

Aptinyx Announces Poster Presentation Highlighting Preclinical Data on NYX-783 in Models of PTSD at the 2022 American Psychiatric Association Annual Meeting

Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that data from preclinical studies of

Aptinyx Reports First Quarter 2022 Financial Results and Highlights Recent Clinical Progress

Current cash position of > $100 million expected to fund operations into 2024 and enable readouts from all three ongoing Phase 2 studies Data readout from Phase 2b study of NYX-2925 in fibromyalgia expected in early

Aptinyx Presents Preclinical Data on NYX-783 in Models of PTSD at 2022 Society of Biological Psychiatry Annual Meeting

Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today presented data from preclinical studies of

Aptinyx to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference

Aptinyx Announces Publication in Molecular Psychiatry Demonstrating Reduction of Spontaneous Recovery of Fear with NYX-783

Preclinical data support the continued clinical development of NYX-783 as a novel mechanistic approach for treating post-traumatic stress disorder (PTSD) NYX-783 is currently under evaluation in a Phase 2b study in

Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy

NYX-2925 did not achieve the primary endpoint of the study Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system